Similar articles

• Modelling cell and isoform type specificity of tauopathies in Drosophila.

  Grammenoudi S, Anezaki M, Kosmidis S, Skoulakis EM. Grammenoudi S, et al. SEB Exp Biol Ser. 2008;60:39-56. SEB Exp Biol Ser. 2008. PMID: 18309786 No abstract available.
• Studying tauopathies in Drosophila: A fruitful model.

  Sun M, Chen L. Sun M, et al. Exp Neurol. 2015 Dec;274(Pt A):52-7. doi: 10.1016/j.expneurol.2015.03.029. Epub 2015 Apr 7. Exp Neurol. 2015. PMID: 25862286 Review.
• Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein.

  Feuillette S, Miguel L, Frébourg T, Campion D, Lecourtois M. Feuillette S, et al. J Neurochem. 2010 May;113(4):895-903. doi: 10.1111/j.1471-4159.2010.06663.x. Epub 2010 Feb 27. J Neurochem. 2010. PMID: 20193038
• Targeted Downregulation of dMyc Suppresses Pathogenesis of Human Neuronal Tauopathies in Drosophila by Limiting Heterochromatin Relaxation and Tau Hyperphosphorylation.

  Chanu SI, Sarkar S. Chanu SI, et al. Mol Neurobiol. 2017 May;54(4):2706-2719. doi: 10.1007/s12035-016-9858-6. Epub 2016 Mar 21. Mol Neurobiol. 2017. PMID: 27000837
• Transgenic animal models of tauopathies.

  Lee VM, Kenyon TK, Trojanowski JQ. Lee VM, et al. Biochim Biophys Acta. 2005 Jan 3;1739(2-3):251-9. doi: 10.1016/j.bbadis.2004.06.014. Biochim Biophys Acta. 2005. PMID: 15615643 Review.